Self-assembled hyaluronic acid nanoparticles for active tumor targeting

Authors
Choi, Ki YoungChung, HyunjinMin, Kyung HyunYoon, Hong YeolKim, KwangmeyungPark, Jae HyungKwon, Ick ChanJeong, Seo Young
Issue Date
2010-01
Publisher
ELSEVIER SCI LTD
Citation
BIOMATERIALS, v.31, no.1, pp.106 - 114
Abstract
Hyaluronic acid nanoparticles (HA-NPs), which are formed by the self-assembly of hydrophobically modified HA derivatives, were prepared to investigate their physicochemical characteristics and fates in tumor-bearing mice after systemic administration. The particle sizes of HA-NPs were controlled in the range of 237-424 nm by varying the degree of substitution of the hydrophobic moiety. When SCC7 cancer cells over-expressing CD44 (the receptor for HA) were treated with fluorescently labeled Cy5.5-HA-NPs, strong fluorescence signals were observed in the cytosol of these cells, suggesting efficient intracellular uptake of HA-NPs by receptor-mediated endocytosis. In contrast, no significant fluorescence signals were observed when Cy5.5-labeled HA-NPs were incubated with normal fibroblast cells (CV-1) or with excess free-HA treated SCC7 cells. Following systemic administration of Cy5.5-labeled HA-NPs with different particle sizes into a tumor-bearing mouse, their biodistribution was monitored as a function of time using a non-invasive near-infrared fluorescence imaging system. Irrespective of the particle size, significant amounts of HA-NPs circulated for two days in the bloodstream and were selectively accumulated into the tumor site. The smaller HA-NPs were able to reach the tumor site more effectively than larger HA-NPs. Interestingly, the concentration of HA-NPs in the tumor site was dramatically reduced when mice were pretreated with an excess of free-HA. These results imply that HA-NPs can accumulate into the tumor site by a combination of passive and active targeting mechanisms. (C) 2009 Elsevier Ltd. All rights reserved.
Keywords
GLYCOL CHITOSAN NANOPARTICLES; RECEPTOR-MEDIATED ENDOCYTOSIS; IN-VIVO; CANCER-CHEMOTHERAPY; ANTITUMOR EFFICACY; DOXORUBICIN; DELIVERY; CELLS; THERAPEUTICS; PACLITAXEL; GLYCOL CHITOSAN NANOPARTICLES; RECEPTOR-MEDIATED ENDOCYTOSIS; IN-VIVO; CANCER-CHEMOTHERAPY; ANTITUMOR EFFICACY; DOXORUBICIN; DELIVERY; CELLS; THERAPEUTICS; PACLITAXEL; Hyaluronic acid; Nanoparticle; Passive targeting; Active targeting; Tumor specificity
ISSN
0142-9612
URI
https://pubs.kist.re.kr/handle/201004/131858
DOI
10.1016/j.biomaterials.2009.09.030
Appears in Collections:
KIST Article > 2010
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE